SB3 Proves Comparable Cardiovascular Safety to Reference Trastuzumab

Data from a secondary analysis of a randomized controlled trial provide an overview of the cardiovascular safety of trastuzumab biosimilar SB3 compared to the reference agent.

Related Keywords

Jennys Guadamuz ,Gregorys Calip ,Ivyp Altomare , ,